A Phase 1 Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04449913 (Glasdegib), An Oral Hedgehog Inhibitor, Administered As A Single Agent In Japanese Patients With Select Hematologic Malignancies And In Combination With Intensive Chemotherapy, Low-dose Ara-c, Or Azacitidine In Patients With Acute Myeloid Leukemia Or High-risk Myelodysplastic Syndrome

Trial Profile

A Phase 1 Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04449913 (Glasdegib), An Oral Hedgehog Inhibitor, Administered As A Single Agent In Japanese Patients With Select Hematologic Malignancies And In Combination With Intensive Chemotherapy, Low-dose Ara-c, Or Azacitidine In Patients With Acute Myeloid Leukemia Or High-risk Myelodysplastic Syndrome

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Glasdegib (Primary) ; Cytarabine; Daunorubicin
  • Indications Acute myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 02 Oct 2017 Planned End Date changed from 1 Oct 2019 to 31 Oct 2019.
    • 02 Oct 2017 Planned primary completion date changed from 1 Oct 2019 to 31 Oct 2019.
    • 17 Aug 2017 Planned number of patients changed from 24 to 33.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top